Heart drug mavacamten shows promise in Real-World study
NCT ID NCT07529938
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 222 adults with obstructive hypertrophic cardiomyopathy, a condition where the heart muscle thickens and blocks blood flow. Researchers compared those who took mavacamten (Camzyos) with those on standard therapy, measuring changes in heart function and symptoms over 30 weeks. The goal was to see if mavacamten works well in everyday medical practice, not just in controlled trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- mavacamten (Camzyos)
- What this could lead to
- If results are positive, this could support using mavacamten more widely to improve heart function and daily life for people with obstructive hypertrophic cardiomyopathy.
- What could go wrong
- This is a retrospective observational study, not a randomized trial, so results may be less reliable. The drug can cause side effects like reduced heart pumping function, and long-term benefits are not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTROPHIC CARDIOMYOPATHY (HCM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fuwai Central China Cardiovascular Hospital
Zhengzhou, Henan, 450000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Heart scan AI could predict sudden cardiac death risk in common heart condition
- Experimental pill aims to ease thick heart muscle symptoms
- Massive HCM database aims to unlock better heart care
- New heart drug aficamten challenges standard Beta-Blocker in major trial
- Heart drug swap tested for safer symptom control
- Real-World HCM drug use under the microscope